103
Participants
Start Date
October 12, 2023
Primary Completion Date
April 12, 2026
Study Completion Date
December 12, 2026
Blood Sample Collection
"For subjects receiving treatments with a 2- or 4-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 2 weeks after treatment start (day 15)~Plasma :~* Before the treatment start (day 1)~* 4 weeks after treatment start (day 29)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1~For subjects receiving treatments with a 3-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 3 weeks after treatment start (day 22)~Plasma :~* Before treatment start (day 1)~* 6 weeks after treatment start (day 43)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1"
RECRUITING
Institut Jules Bordet, Anderlecht
RECRUITING
Cliniques Universitaires Saint Luc, Woluwe-Saint-Lambert
RECRUITING
CHU Ambroise Pare, Mons
ACTIVE_NOT_RECRUITING
Hopital Franco-Britannique - Fondation Cognacq-Jay, Levallois-Perret
RECRUITING
UZ Antwerpen, Antwerp
RECRUITING
CHIREC Delta, Brussels
ACTIVE_NOT_RECRUITING
Centre Georges François Leclerc, Dijon
ACTIVE_NOT_RECRUITING
Hopital privé Jean Mermoz, Lyon
ACTIVE_NOT_RECRUITING
Hopital St-Louis, Paris
ACTIVE_NOT_RECRUITING
CHU Poitiers, Poitiers
ACTIVE_NOT_RECRUITING
ICO Saint-Herblain, Saint-Herblain
ACTIVE_NOT_RECRUITING
ICANS Strasbourg, Strasbourg
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Jules Bordet Institute
OTHER